14 November 2025
We are delighted to announce the appointment of Mathieu Saint-Arnaud as a new member of the MPP Governance Board. Mathieu currently serves as Managing Director at Deutsche Bank and brings nearly two decades of experience from UBS, where he held senior leadership roles. His distinguished career spans global finance, wealth management, and investment banking, complemented by early work as an economist at the South Korean mission to the World Trade Organization.
Mathieu holds an MBA from the University of Oxford, a Master’s degree from the Geneva Graduate Institute, and a Bachelor’s degree from McGill University. His professional journey reflects a deep commitment to innovation and impact, including significant engagement with investors and philanthropies supporting transformative models.
The Governance Board is MPP’s highest decision-making authority, responsible for setting policies and strategies, overseeing work plans and financial matters, and monitoring performance. Mathieu’s expertise and global outlook will be invaluable as we advance MPP’s mission to improve access to essential medicines worldwide.
More information about MPP’s Governance Board
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.